Dr. Amina Farouk MD, MSc Pharmacovigilance

Agenus Announces Q1 2026 Financial Report Date for Botensilimab and Balstilimab Cancer Programs

Agenus will provide Q1 2026 financial results and corporate update on botensilimab and balstilimab cancer immunotherapy programs with regulatory timeline guidance.

ANVISA Regulatory Changes: Key Impact on Foreign Drug Manufacturers in Brazil

ANVISA's recent regulatory changes significantly affect foreign drug manufacturers in Brazil, influencing drug approvals and market strategies for key treatments.

Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates

This article delves into the market potential for biosimilars in Brazil following recent ANVISA regulatory updates, highlighting Infliximab's role in treating autoimmune conditions.

Plozasiran TGA Approval in Australia for FCS Patients

Arrowhead Pharmaceuticals has announced the Therapeutic Goods Administration (TGA) approval of REDEMPLO® (plozasiran) in Australia for patients with Familial Chylomicronemia Syndrome (FCS). This landmark decision broadens global access to a crucial treatment for this rare genetic disorder.

Alkeus Pharmaceuticals Presents Gildeuretinol Data for Stargardt Disease at ARVO 2026

Alkeus Pharmaceuticals announces clinical data presentation for investigational oral gildeuretinol treating Stargardt disease at ARVO 2026 meeting.

COFEPRIS Generic Drug Approval: Market Impact & Competitive Shift 2025

This article analyzes the implications of COFEPRIS's generic drug approval for hypertension treatments, highlighting market dynamics and competitive shifts expected in 2025.

SFDA Accelerated Approval Oncology: Expanding Access with Anktiva in Saudi Arabia

The SFDA's accelerated approval of Anktiva enhances treatment options for oncology patients in Saudi Arabia, improving access to innovative therapies.

FDA Accelerated Approval Oncology: 2026 Review of Evolving Pathways

This article reviews the FDA's Accelerated Approval pathways for oncology drugs, focusing on advancements and the impact on treatments like Keytruda.

Saudi Arabian pharmaceutical market: SFDA's accelerated drug approvals impact

The SFDA's expedited drug approval process is reshaping the Saudi Arabian pharmaceutical landscape, enhancing access to critical medications such as insulin for diabetes management.

Rise of Biosimilars in US: FDA Approval Trends & Market Impact

The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.

Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders

Survodutide delivered 39.2 lb average weight loss in 76-week trial, potentially superior to Wegovy and Zepbound in competitive obesity market.

Cytokinetics MYQORZO (Aficamten) Takes Center Stage at European Society of Cardiology Heart Failure 2026 Congress

Cytokinetics presents nine studies on MYQORZO (aficamten) at ESC Heart Failure 2026, including late-breaking science on the newly approved oHCM treatment.

EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity

This article examines how recent EU pharmaceutical legislation reforms affect orphan drug development and market exclusivity, shaping the future of rare disease therapies.

EMA Conditional Approvals CAR-T: What You Need to Know on B-Cell Lymphomas

Explore the latest on EMA Conditional Approvals for CAR-T therapies targeting B-Cell Lymphomas, including treatment efficacy and patient outcomes.

FDA Biosimilar Approval Pathway: Key Regulatory Changes & Market Impact 2026

This article delves into the FDA's regulatory changes for biosimilars, their implications for drug pricing, and the future landscape of patient care in 2026.

EMA Conditional Approval Pathway: Case Study on Repotrectinib Oncology Drug

This article delves into the EMA Conditional Approval Pathway, highlighting the case study of Repotrectinib for treating ROS1-positive oncology patients.

EMA Issues Positive Opinion for Redemplo (Plozasiran) in European Drug Approval Process

European Medicines Agency issues positive opinion for Redemplo (plozasiran) marking significant step toward EU market authorization for this novel therapy.

EMA Recommends Approval of Plozasiran (Redemplo) for Rare Triglyceride Disorder FCS

European Medicines Agency recommends plozasiran (Redemplo) for marketing authorization to treat adults with familial chylomicronaemia syndrome in EU.

CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026

CLINUVEL gets final EMA scientific advice for pivotal Phase III vitiligo study comparing SCENESSE with NB-UVB therapy, set to begin second half 2026.

RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results

RenovoRx announces ASCO acceptance of pharmacokinetic data from Phase III TIGeR-PaC trial testing TAMP therapy platform for pancreatic cancer treatment.

SFDA Expedited Drug Approval: Impact on Saudi Pharma Market & Innovation

The SFDA's expedited drug approval process is revolutionizing the Saudi pharmaceutical market, fostering innovation and enhancing access to vital medications.

COFEPRIS Biosimilar Approval: What You Need to Know About 2024 Guidelines

Stay informed about COFEPRIS's 2024 biosimilar approval guidelines, essential for understanding the regulatory landscape for drugs like adalimumab.

Blinatumomab Long-Term Safety Study in Pediatric Leukemia Patients Reaches Final Stage

European study evaluating long-term safety of blinatumomab versus chemotherapy in pediatric acute lymphoblastic leukemia patients nears completion.

Belite Bio Submits New Drug Application for Tinlarebant to Treat Stargardt Disease Following Positive Phase 3 Results

Belite Bio initiates rolling NDA submission for tinlarebant after Phase 3 DRAGON trial showed 35.7% reduction in retinal lesion growth for Stargardt disease patients.